An Official Website of the United States Government
Improved Formulations to Enhance Bio-availability for Antisense Therapeutics
- Small Business Information
-
Woman-Owned: NoMinority-Owned: YesHUBZone-Owned: No
- Phase 1
-
Fiscal Year: 2010Title: Improved Formulations to Enhance Bio-availability for Antisense TherapeuticsAgency / Branch: DOD / CBDContract: HDTRA1-10-P-0041Award Amount: $70,000.00
Abstract:
In general, many biological and chemical agents affect the lungs directly or indirectly, even if the respiratory system is not the primary target organ of a military or terrorist attack. Both in the case of military and civilian attacks the lung can be one of the first organs affected by a chemical or biological agent. LNK Chemsolutions (LNK) with expertise in nanoparticle formulations and the University of Illinois Chicago with expertise in Acute Lung Injury (ALI) molecular biology and treatment modality development have teamed up to develop novel oral and inhalation formulation of targeted nanoparticles (NPs) containing siRNA and/or miRNA to improve the treatment of ALI unobtainable with current delivery systems.Small Business Information at Submission:LNK Chemsolutions, LLC
4701 Innovation Drive Lincoln, NE 68521EIN/Tax ID: 470833036DUNS: N/ANumber of Employees:Woman-Owned: NoMinority-Owned: NoHUBZone-Owned: No
Award Information
|
Agency: Department of Defense |
Branch: Office for Chemical and Biological Defense |
Award ID: 96627 |
Program Year/Program: 2010 / SBIR |
|
Agency Tracking Number: C101-102-0079 |
Solicitation Year: N/A |
Solicitation Topic Code: CBD 10-102 |
Solicitation Number: N/A |